SHOCKWAVE MEDICAL INC (SWAV)       187.32  -2.17 (-1.15%)

187.32  -2.17 (-1.15%)

US82489T1043 - Common Stock - After market: 187.32 0 (0%)


Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to SWAV. SWAV was compared to 223 industry peers in the Health Care Equipment & Supplies industry. SWAV gets an excellent profitability rating and is at the same time showing great financial health properties. SWAV shows excellent growth, but is valued quite expensive already. This makes SWAV very considerable for growth investing!.




Profitability

Profitability Rating

8

SWAV has a Return On Assets of 18.50%. This is amongst the best returns in the industry. The industry average is 6.39%. SWAV outperforms 86% of its industry peers.
SWAV has a Return On Equity of 24.73%. This is amongst the best returns in the industry. The industry average is 10.59%. SWAV outperforms 82% of its industry peers.

SWAV's Profit Margin of 20.48% is amongst the best of the industry. SWAV does better than the industry average Profit Margin of 12.35%.
The Piotroski-F score of SWAV is 7.00. This is a strong score and indicates good health and profitability for SWAV.
VS Industry

ROA (18.5%) VS Industry: 86% outperformed.

0.53
117.69

ROE (24.73%) VS Industry: 82% outperformed.

0.69
140.68

Profit Margin (20.48%) VS Industry: 77% outperformed.

1.07
1,450.19

Valuation

Valuation Rating

2

SWAV's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The Price/Earnings Ratio is 80.39, which means the current valuation is very expensive for SWAV.
Compared to an average industry Price/Earning Ratio of 27.21, SWAV is valued more expensive than its industry peers. On top of this 88% of the companies listed in the same industry are cheaper than SWAV!
With a Forward Price/Earnings Ratio of 49.27, SWAV is valued very expensively.

When comparing the current price to the book value of SWAV, we can conclude it is valued rather expensively. It is trading at 19.02 times its book value.
Compared to an average industry price book ratio of 2.90, SWAV is valued more expensive than its industry peers. 93% of the companies listed in the same industry are valued cheaper.
Compared to an average industry Enterprise Value to EBITDA ratio of 20.41, SWAV is valued more expensive than its industry peers. 94% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (80.39) VS Industry: 12% outperformed.

2,372.91
2.20

Price/Book (19.02) VS Industry: 7% outperformed.

1,369.61
0.21

Enterprise Value/ EBITDA (64.96) VS Industry: 6% outperformed.

6,416.20
0.02

Growth

Growth Rating

9

SWAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 311.82%, which is quite impressive.
SWAV is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 89.45% yearly.
Looking at the last year, SWAV shows a very strong growth in Revenue. The Revenue has grown by 144.70%.

The Revenue has been growing by 168.44% on average over the past 5 years. This is a very strong growth!
The Revenue is expected to grow by 39.79% on average over the next 5 years. This is a very strong growth
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 311.82% 1110.77% 283.04% 161.85% 89.45%
RevenueN/A 168.44% 144.7% 113.46% 67.27% 52.38% 39.79%

Health

Health Rating

8

A Current Ratio of 7.29 indicates that SWAV has no problem at all paying its short term obligations.
The Current Ratio of SWAV is much better than the industry average of 3.69.
SWAV has a Quick Ratio of 6.02. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
SWAV is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 2.91.

SWAV has an Altman-Z score of 36.18. This indicates that SWAV is financially healthy and little risk of bankruptcy at the moment.
The Altman-Z score of SWAV is much better than the industry average of 1.97. SWAV has a better rating than 99% of its industry peers.
The Piotroski-F score of SWAV is 7.00. This is a strong score and indicates good health and profitability for SWAV.
The Debt to Equity ratio of SWAV is in line with the industry averages.
VS Industry

Debt/Equity (0.04) VS Industry: 56% outperformed.

336.87
0.00

Quick Ratio (6.02) VS Industry: 76% outperformed.

0.06
33.20

Current Ratio (7.29) VS Industry: 79% outperformed.

0.12
33.20

Altman-Z (36.18) VS Industry: 99% outperformed.

-101.74
78.21

Dividend

Dividend Rating

0

SWAV does not give a dividend.

SHOCKWAVE MEDICAL INC187.32

NASDAQ:SWAV (2/3/2023, 7:09:57 PM)-2.17 (-1.15%)

After market: 187.32 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Equipment & Supplies
Earnings (Last) 11-07 2022-11-07/amc Earnings (Next) 02-15 2023-02-15
Inst Owners 91.39% Inst Owner Change -0.38%
Ins Owners 1.48% Ins Owner Change -15.31%
Market Cap 6.77B Analysts 78.57
Price Target 264.69 (41.3%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 43.21%
Min EPS beat(2) 34.91% Max EPS beat(2) 51.52%
EPS beat(4) 4 Avg EPS beat(4) 121.51%
Min EPS beat(4) 34.91% Max EPS beat(4) 292.16%
Revenue beat(2) 2 Avg Revenue beat(2) 6.98%
Min Revenue beat(2) 3.86% Max Revenue beat(2) 10.1%
Revenue beat(4) 4 Avg Revenue beat(4) 7.4%
Min Revenue beat(4) 3.86% Max Revenue beat(4) 10.1%
PT rev (1m) -4.77% PT rev (3m) 1.25%
EPS NQ rev (1m) 0% EPS NQ rev (3m) 21.2%
EPS NY rev (1m) 0% EPS NY rev (3m) 16.71%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) 2.65%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 2.38%

Valuation
Industry RankSector Rank
PE 80.39
Fwd PE 49.27
P/S 15.75
P/FCF 97.75
P/OCF 78.61
P/B 19.02
P/tB 19.02
EV/EBITDA 64.96
EPS(TTM) 2.33 EY 1.24%
EPS(NY) 3.8 Fwd EY 2.03%
FCF(TTM) 1.92 FCFY 1.02%
OCF(TTM) 2.38 OCFY 1.27%
SpS 11.89 BVpS 9.85
TBVpS 9.85 PEG (NY) 0.07
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA 18.5%
ROE 24.73%
ROIC 17.93%
ROICexc 44.23%
ROICexgc 44.23%
OM 22.26%
PM 20.48%
GM 86.01%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y 26.4% GM growth 5Y N/A
F-Score 7 Asset Turnover 0.9

Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.21
Debt/EBITDA 0.15
Cap/Depr 400.48%
Profit Quality 78.68%
Current Ratio 7.29
Quick Ratio 6.02
Altman-Z 36.18
F-Score 7 WACC 8.78%
ROIC/WACC 5.04 Cap/Depr(3y) 417.33%
Cap/Depr(5y) 325.27% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 311.82% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 1740%
EPS Next Y 1110.77% EPS Next 2Y 283.04%
EPS Next 3Y 161.85% EPS Next 5Y 89.45%
Revenue growth 1Y 144.7% Revenue growth 3Y 168.44%
Revenue growth 5Y N/A Revenue growth Q2Q 101.57%
Revenue Next Year 113.46% Revenue Next 2Y 67.27%
Revenue Next 3Y 52.38% Revenue Next 5Y 39.79%
EBIT growth 1Y 411.43% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year 1405.64%
EBIT Next 3Y 201.84% EBIT Next 5Y 114.69%
FCF growth 1Y 183.71% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y 220.69%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA